Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Didn’t he say in last interview this week, you won’t see me in the studio in the next few days after being interviewed back to back.
Nice to see continuous contracts.
Wonder how the finals and revenue forecasts will look like.
Excellent RNs. Broker Rating 70p. Time to load and hold.
Nice to see the Astra Zeneca relationship is going well.
That's a half-decent amount - another 6 of those and we're in the money!
Be interesting TGTD take … I can’t believe tyst he can spend so much of his life on here spewing hatred and bad will for this company
ANGLE plc ("the Company")
NEW COMMERCIAL AGREEMENT WITH LARGE PHARMA
ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce that it has signed a supplier agreement to develop a Parsortix-based Androgen Receptor1 (AR) detection assay for use in prostate cancer studies. The supplier agreement reported here is with AstraZeneca (LSE/STO/Nasdaq: AZN). This follows an earlier agreement to develop a methodology for CTC micronuclei detection using the Company's DNA Damage Response (DDR) assay, announced on 24 April 2024.
Under the terms of this agreement, worth £550,000 to ANGLE, the Company will develop a CTC-based AR assay. Assay development will take place in the ANGLE's UK laboratories, with project completion expected in Q1 2025. A successful development phase will demonstrate the importance of the Parsortix system in assessing the efficacy of prostate cancer therapeutics and offers the potential for long-term, ongoing business for the Company supporting clinical studies.
AR is a nuclear protein involved in cell growth and proliferation, cell cycle progression, protein synthesis, and cell death. The analysis of Parsortix® harvested CTCs using the Company's AR assay could enable longitudinal, minimally invasive assessment of AR status throughout clinical studies and during follow-up. There are more than 130 active, interventional oncology clinical studies in 30,000 participants, which include androgen receptor assessment, registered on clinicaltrials.gov.
ANGLE Chief Executive Officer, Andrew Newland, commented:
"This is further validation of ANGLE's Parsortix system which shows potential for long-term large-scale revenues in bringing innovative new cancer drugs to the market. We anticipate that success in this first phase of assay development may lead to much larger contracts for use of the assay in clinical trials."
ANGLE Chief Scientific Officer, Karen Miller commented:
"We are delighted our expertise is being put to use in the isolation, harvest, and profiling of CTCs for androgen receptor investigation with the potential for ANGLE's assays to be used in clinical trials. The new androgen receptor assay will also be an important addition to the menu of assays we can offer other customers."
550k contract. EC will be happy today.
Time to buy some back imo
EC
"A leading liquid biopsy Company with an FDA cleared machine, contracts with both Eisai and now Astrazeneca........"
Really EC are you sure Parsortix is FDA "cleared" and there are contracts with both AZ and Eisai...these are tiny of little monetary value and for trial purposes only and may never lead anywhere..the way your misrepresenting information is appalling!
Yes it spiked at 37p for a few hours and held 31p for a good while in Jan
Director bought at 28p last year.
Mesquida.
"Surely 37p was the top ofbthe January spoke ?2
======================================
Sorry. My memory said 51p but checking the chart it was arounf 31p! Still over two fold the currect sp of course.
Surely 37p was the top ofbthe January spoke ?
Nudgesta.
"The sp has never been that low??"
======================
Results due this month.
Lowest I remember was about 9.8p Nov 2023. Highest since then 51p ish (spike up due to RNS of 4th Jan 2024 - Cancer breakthrough). Recently spiked to 17p (contract with Astrazeneca). Illiquid share means it moves a lot on low volume (either way). Thus a good news RNS often spikes the sp up a lot.......
Currently 14p.
All IMHO.
The sp has never been that low??
I would not be surprised is a bid comes in.
A leading liquid biopsy Company with an FDA cleared machine, contracts with both Eisai and now Astrazeneca........
The market cap is ridiculous if you ask me.
All IMHO.
Due this month.
The original announcement "ANGLE announces partnership with BioView" 19th April 2023:-
https://www.lse.co.uk/rns/AGL/angle-announces-partnership-with-bioview-dvvtkgt3ttabibt.html
The update "Parsortix HER2 assay showcased at AACR 2024" 8th April 2024:
https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html
Lovely. Need the share price to drop to 6-7p. I will then load up more like TwoGood2.
I will bring some flowers and give my condolences 🙏 ☹️!
Due this month - May 2024.
See:-
https://angleplc.com/information-for-investors-angle-plc/financial-reports/#text_grid-1
Yes they were shocking...I did say a placement was on the cards.. imho.
????
I was thinking 10p at best!
TwoGood2Die.
I don't mean for the whole Company. LOL!
Hello.
Pretty obvious the market doesn't agree with the desperate rampers here!